Health & Fitness
Health and Fitness
Health and Fitness
Wed, February 23, 2011Tue, February 22, 2011Mon, February 21, 2011Sun, February 20, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Mon, February 14, 2011Fri, February 11, 2011Thu, February 10, 2011Wed, February 9, 2011Tue, February 8, 2011Mon, February 7, 2011Sun, February 6, 2011Fri, February 4, 2011Thu, February 3, 2011Inspire Announces Date for Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results and Provi
Published in Health and Fitness on Monday, February 14th 2011 at 3:40 GMT by Market Wire
RALEIGH, N.C.--([ BUSINESS WIRE ])--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to report fourth quarter and full year 2010 financial results and provide a corporate update on Thursday, February 17, 2011 before the market opens. Inspire's President and CEO, Adrian Adams, and Executive Vice President and CFO, Thomas R. Staab, II, will host a conference call and live webcast with an accompanying slide presentation on Thursday, February 17, 2011 at 8:00 a.m. ET.
Conference Call and Live Webcast
The live webcast and replay will be available on Inspire's website at [ www.inspirepharm.com ]. The webcast will include audio of the conference call and a slide presentation to be reviewed during the call. To access the conference call, U.S. participants may call (877) 648-7970 and international participants may call (706) 902-0415. The conference ID number is 43734225. A telephone replay of the conference call will be available until February 24, 2011. To access this replay, U.S. participants may call (800) 642-1687 and international participants may call (706) 645-9291. The conference ID number is 43734225.
About Inspire
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire's goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. Inspire's clinical pipeline includes denufosol tetrasodium for cystic fibrosis in Phase 3 development and AZASITE® (azithromycin ophthalmic solution) 1% for blepharitis in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye and DIQUASa" Ophthalmic Solution 3% (diquafosol tetrasodium) for dry eye. For more information, visit [ www.inspirepharm.com ].
